secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2026-10-20T20:09:27+00:00
Accession:  0000875320-26-000278
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Vertex appoints ex-Boston Scientific CFO Daniel Brennan to board; board expands to 11 members
--------------------------------------------------------------------------------

- Daniel Brennan appointed to Vertex's board of directors on October 20, 2026, expanding the board from ten to eleven members.
- Brennan also joins the Audit and Finance Committee; he retired in June 2025 as EVP and CFO of Boston Scientific, where he served from January 2014.
- Brennan sits on boards of Waters Corporation (since November 2022) and Madrigal Pharmaceuticals (since August 2025); previously on Nuance's board until its 2022 Microsoft acquisition.
- Received a $400,000 restricted stock unit award upon joining, vesting in October 2027; Vertex reports no Item 404(a) related-party transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000278/0000875320-26-000278-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000278/vrtx-20261020.htm
  HTML page:      https://secwatch.observer/filing/0000875320-26-000278

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer